Treatment of chronic non-infectious uveitis and scleritis

被引:16
作者
Daniele, Rossi C. [1 ]
Camillo, Ribi [2 ]
Yan, Guex-Crosier [1 ]
机构
[1] Univ Lausanne, Ophthalmol Dept, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland
[2] CHU Vaudois, Div Immunol & Allergy, Lausanne, Switzerland
关键词
uveitis; scleritis; azathioprine; methotrexate; mycophenolate mofetil; immunosuppressive agents; anti-TNF agents; biological therapy; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; MYCOPHENOLATE-MOFETIL; MONOCLONAL-ANTIBODY; OPEN-LABEL; ADALIMUMAB; THERAPY; METHOTREXATE; CORTICOSTEROIDS; PREVALENCE;
D O I
10.4414/smw.2019.20025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ocular inflammations such as uveitis and scleritis can lead to significant visual impairment if not treated properly. To limit potentially sight- threatening complications, good control of the inflammation in the acute phase is necessary. Corticosteroids have been the mainstay of ocular therapies for many years, but high doses of corticosteroids, which are required to maintain quiescence in severe uveitis, can be associated with many systemic and ocular complications. In order to limit steroid side- effects, classic immunosuppressant and immunobiologic agents have been widely used as steroid- sparing agents. In this review, we summarise the immunosuppressive drug therapy utilised in the treatment of ocular inflammatory diseases.
引用
收藏
页数:6
相关论文
共 61 条
[1]   Incidence and Prevalence of Uveitis Results From the Pacific Ocular Inflammation Study [J].
Acharya, Nisha R. ;
Tham, Vivien M. ;
Esterberg, Elizabeth ;
Borkar, Durga S. ;
Parker, John V. ;
Vinoya, Aleli C. ;
Uchida, Aileen .
JAMA OPHTHALMOLOGY, 2013, 131 (11) :1405-1412
[2]   Autoantibody production in Anti-TNF-α-Treated patients [J].
Alessandri, Cristiano ;
Scrivo, Rossana ;
Spinelli, Francesca Romana ;
Ceccarelli, Fulvia ;
Magrini, Leonardo ;
Priori, Roberta ;
Valesini, Guido .
AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 :319-329
[3]  
Anonymous, 2005, International Ophthalmology Clinics, V45, P1, DOI 10.1097/01.iio.0000155938.83083.94
[4]  
ARMALY MF, 1965, FED PROC, V24, P1274
[5]   Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational? [J].
Baeten, Dominique ;
van Hagen, P. Martin .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (12) :2067-2073
[6]   Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease [J].
Baker, K. B. ;
Spurrier, N. J. ;
Watkins, A. S. ;
Smith, J. R. ;
Rosenbaum, J. T. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (12) :1481-1485
[7]   Pharmacotherapy of scleritis: current paradigms and future directions [J].
Beardsley, Robert M. ;
Suhler, Eric B. ;
Rosenbaum, James T. ;
Lin, Phoebe .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (04) :411-424
[8]   Cyclosporine nephrotoxicity [J].
Burdmann, EA ;
Andoh, TF ;
Yu, L ;
Bennett, WM .
SEMINARS IN NEPHROLOGY, 2003, 23 (05) :465-476
[9]   COMPARISON OF INVITRO POTENCY OF CORTICOSTEROIDS WITH ABILITY TO RAISE INTRAOCULAR-PRESSURE [J].
CANTRILL, HL ;
PALMBERG, PF ;
ZINK, HA ;
WALTMAN, SR ;
PODOS, SM ;
BECKER, B .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1975, 79 (06) :1012-1017
[10]  
Cassidy J T, 1977, Arthritis Rheum, V20, P224